Sutent (sunitinib) has been approved for the treatment of pancreatic cancer.
It is now licensed for use in patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors who have evidence of disease progression.
Approval for this indication was based on the results of a randomised, double-blind, phase 3 trial in 171 patients who received either 37.5mg sunitinib once daily or placebo. Analysis showed that the duration of progression-free survival was more than doubled in the sunitinib group (11.4 months versus 5.5 months for placebo, p=0.0001).
Sunitinib inhibits multiple receptor tyrosine kinases involved in tumour growth, angiogenesis, and metastasis, including VEGF and PDGF receptors. It was previously approved only for the treatment of advanced/metastatic renal cell carcinoma and unresectable and/or metastatic malignant gastrointestinal stromal tumor.
Further information: Pfizer